Study reveals positive impact of repeat COVID-19 vaccinations

Ful­crum Ther­a­peu­tics re­port­ed a Phase 3 fail Thurs­day morn­ing, send­ing its stock plum­met­ing. The biotech said that a study test­ing the … Sign up to

Clinicians and others curious about the data underlying February’s FDA approval of sarilumab (Kevzara) for polymyalgia rheumatica (PMR) can now be sated, at least partially,